Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
13.00
-0.22 (-1.66%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Company Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals plc
| Country | Ireland |
| Founded | 2015 |
| IPO Date | Jun 7, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 154 |
| CEO | Gregory Divis |
Contact Details
Address: 10 Earlsfort Terrace Dublin, 2 Ireland | |
| Phone | 353 1 901 5201 |
| Website | avadel.com |
Stock Details
| Ticker Symbol | AVDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001012477 |
| CUSIP Number | 05337M104 |
| ISIN Number | US05337M1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory J. Divis Jr. | Chief Executive Officer and Director |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer |
| Richard J. Kim | Chief Commercial Officer |
| Jerad G. Seurer | General Counsel and Company Secretary |
| Gregory J. Davis | Vice President of Corporate and Business Development |
| Mark W. Elrod | Vice President of Sales |
| Angie Woods | Vice President of People and Culture |
| Dr. Jordan S. Dubow M.D. | Consultant |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations |
| Jennifer Gudeman PharmD | Senior Vice President of Medical and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 17, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 8-K | Current Report |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 18, 2024 | ARS | Filing |
| Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |